In recent years, increasing age, obesity and diabetes have become more frequent in Canadians, affecting overall health, including that of the liver. With more than 90 therapies in development for NAFLD/NASH, there has never been a more important time to STAND UP to NASH.
Join CASL, CanNASH and Intercept for this new CPD activity, coming soon, to ensure that you and your colleagues – as well as any healthcare provider who treats patients with NAFLD and NASH – have the latest information regarding Surveillance, Treatment Approaches and New Diagnostic Updates concerning these diseases.